Miss Ksenija Nesic
Honorary (Fellow)
Department of Medical Biology (WEHI)
16 Scholarly works
0 Projects
HIGHLIGHTS
2026
Journal article
Olaparib in HR-deficient, metastatic triple-negative breast and platinum-sensitive relapsed ovarian cancers without germline mutations in BRCA1/2: phase 2 EMBRACE trial
DOI: 10.1038/s41416-026-03535-62025
Journal article
DNA repair and the contribution to chemotherapy resistance
DOI: 10.1186/s13073-025-01488-82025
Journal article
Olaparib, durvalumab, and cyclophosphamide, and a prognostic blood signature in platinum-sensitive ovarian cancer: the randomized phase 2 SOLACE2 trial
DOI: 10.1038/s41467-025-64130-62024
Journal article
BRCA1 secondary splice-site mutations drive exon-skipping and PARP inhibitor resistance
DOI: 10.1186/s12943-024-02048-12024
Journal article
High-level tumour methylation of BRCA1 and RAD51C is required for homologous recombination deficiency in solid cancers
DOI: 10.1093/narcan/zcae0332024
Journal article
The role of aberrant DNA methylation in cancer initiation and clinical impacts
DOI: 10.1177/175883592312205112023
Journal article
Targeting homologous recombination deficiency in uterine leiomyosarcoma
DOI: 10.1186/s13046-023-02687-0
RECENT SCHOLARLY WORKS
2023
Journal article
The microtubule inhibitor eribulin demonstrates efficacy in platinum-resistant and refractory high-grade serous ovarian cancer patient-derived xenograft models
DOI: 10.1177/175883592312086742021
Journal article
Acquired RAD51C promoter methylation loss causes PARP inhibitor resistance in high-grade serous ovarian carcinoma
DOI: 10.1158/0008-5472.CAN-21-07742021
Journal article
Characterization of a RAD51C-silenced high-grade serous ovarian cancer model during development of PARP inhibitor resistance
DOI: 10.1093/narcan/zcab028